Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective

Aisling Barry*, Smith Apisarnthanarax, Grainne M. O'Kane, Gonzalo Sapisochin, Robert Beecroft, Riad Salem, Sang Min Yoon, Young Suk Lim, John Bridgewater, Brian Davidson, Marta Scorsetti, Luigi Solbiati, Adam Diehl, Pablo Munoz Schuffenegger, Jonathan G. Sham, David Cavallucci, Zita Galvin, Laura A. Dawson, Maria A. Hawkins

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

31 Scopus citations

Abstract

Around the world, recommendations for cancer treatment are being adapted in real time in response to the pandemic of COVID-19. We, as a multidisciplinary team, reviewed the standard management options, according to the Barcelona Clinic Liver Cancer classification system, for hepatocellular carcinoma. We propose treatment recommendations related to COVID-19 for the different stages of hepatocellular carcinoma (ie, 0, A, B, and C), specifically in relation to surgery, locoregional therapies, and systemic therapy. We suggest potential strategies to modify risk during the pandemic and aid multidisciplinary treatment decision making. We also review the multidisciplinary management of intrahepatic cholangiocarcinoma as a potentially curable and incurable diagnosis in the setting of COVID-19.

Original languageEnglish (US)
Pages (from-to)765-775
Number of pages11
JournalThe Lancet Gastroenterology and Hepatology
Volume5
Issue number8
DOIs
StatePublished - Aug 2020

Funding

RS is a consultant for Boston Scientific, Cook, Sirtex, Eisai, Genentech, and Becton Dickinson. PMS is on the Advanced Radiotherapy Committee for the International Association for the Study of Lung Cancer. LAD has a licensing agreement with Raysearch for image registration software in a system for radiation treatment planning. GMK is a consultant for Eisai. GS declares research funding from Roche and Bayer, outside the submitted work. AD declares funding from the Clinical Research Division at Fred Hutchinson Cancer Research Center, outside the submitted work. MAH and JB declare funding from the NIHR Biomedical Research Centre at University College London Hospitals National Health Service Foundation Trust, outside the submitted work. All other authors declare no competing interests.

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Fingerprint

Dive into the research topics of 'Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective'. Together they form a unique fingerprint.

Cite this